<DOC>
	<DOCNO>NCT01090570</DOCNO>
	<brief_summary>PLX3397 selective inhibitor Fms Kit activity . The objective study evaluate safety , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) , drug-drug interaction ( DDI ) orally administer PLX3397 2 week dose patient rheumatoid arthritis ( RA ) maintenance methotrexate . This study plan provide data inform dose selection subsequent 12 week dose range study RA .</brief_summary>
	<brief_title>Safety , Pharmacokinetic ( PK ) , Pharmcodynamic ( PD ) , Drug-Drug Interaction PLX3397 Patients With Rheumatoid Arthritis Who Are Receiving Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Male female patient ≥ 18 year old diagnosis rheumatoid arthritis ACR criterion ≥ 3 month . Prior Baseline , patient must oral subcutaneous methotrexate ( ≥ 10 mg/week ≤ 25 mg/week ) least 12 week ( stable dose least 4 week ) folate ( ≥ 5 mg/week ) least 6 week , willing continue regimen duration study . Adequate hematologic , hepatic , renal function ( absolute neutrophil count ≥ 1.5 X 109/L , Hgb &gt; 9 g/dL , platelet count ≥ 100 X 109/L , AST/ALT WNL , albumin ≥ 3 g/dL , calculate CrCl &gt; 60 mL/min use CockcroftGault formula ) . Women childbearing potential must negative pregnancy test within 7 day prior initiation dosing must agree use double barrier method birth control time negative pregnancy test 30 day last dose study drug . Women nonchildbearing potential may include either surgically sterile postmenopausal ≥1 year . Fertile men must agree use acceptable method birth control study drug . Acceptable method contraception must include either abstinence first dose study drug 4 week last dose study drug , use condom instruction female partner childbearing potential also protect . Willing able provide write informed consent prior study related procedure comply study requirement . Use biologic response modifier within follow period prior Day 1 Baseline : 4 week Kineret ( anakinra ) Enbrel ( etanercept ) ; 12 week Remicade ( infliximab ) , Humira ( adalimumab ) , Simponi ( golimumab ) , Orencia ( abatacept ) , Actemra ( tocilizumab ) , Cimzia ( certolizumab ) ; 12 month Rituxan . Use Arava ( leflunomide ) within 12 week prior Day 1 Baseline immunosuppressive agent hydroxychloroquine sulfasalazine within 4 week Day 1 Baseline . Investigational drug use within 4 week Day 1 Baseline . Concomitant use DMARDs ( methotrexate ) , biological response modifier , know strong inducer inhibitor CYP3A4 . Positive HepBsAg HCV , presence clinically significant hepatic biliary disease . Uncontrolled intercurrent illness . Refractory nausea vomiting , malabsorption , external biliary shunt , significant bowel resection would preclude adequate absorption . QTc ≥ 450 msec Screening . The presence medical psychiatric condition , opinion Principal Investigator , make patient inappropriate inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>